DEMECAN applies for an increase in production quantities of medical cannabis and calls for equal competition conditions for domestic producers.

Ebersbach, Germany, May 2nd, 2023 Last week, the Saxon company DEMECAN officially filed an application with the Federal Institute for Drugs and Medical Devices (BfArM) to increase the production quantities of medical cannabis in Germany. With the aim of creating equal competition conditions for domestic producers, DEMECAN is calling for an increase in production quantities and an end to the discrimination against German producers.

"There is unequal treatment between German and foreign producers of medical cannabis in Germany," says Dr. Constantin von der Groeben, Managing Director of DEMECAN. "While foreign producers can produce unlimited quantities and import them to Germany, domestic producers such as DEMECAN are only allowed to produce 990 kg. This unequal treatment must now be ended!" adds Dr. von der Groeben.

DEMECAN advocates for higher production of medical cannabis in Germany to ensure the supply of medical cannabis to patients, ensure quality locally, and strengthen the German economy. The company is willing to bear the economic risk for the additional quantities itself and suggests that additional quantities of medical cannabis be awarded through an open-house procedure.

DEMECAN's application follows information from the BfArM from an IFG application for controlling foreign producers exporting medical cannabis to Germany. These revealed that foreign producers are subject to neither quantity nor price restrictions. A small inquiry from the Bundestag fraction DIE LINKE in November 2022 also revealed that permits have now been issued for the import of 78,672.20 kg of dried cannabis flowers, including from Lesotho, Jamaica, and Canada, among others. Permits without quantity restrictions were also granted for North Macedonia.

DEMECAN sees its application as an opportunity to restore competition equilibrium in the industry and strengthen the domestic market. The company remains confident that its application will be positively answered and looks forward to continuing to produce high-quality medical cannabis in Germany.


DEMECAN is the only independent German company that covers the entire value chain for medical cannabis – from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in “Made in Germany” quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company’s facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC), Cannabis Business Industry Association e.V. (BvCW) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).

Further Information:
Press contact:

Weitere Presse­mitteilungen